Proactive Investors - Run By Investors For Investors
Why invest in CDY?
Cellmid Ltd: THE INVESTMENT CASE
INVESTMENT OVERVIEW

Cellmid driving towards profitability with anti-ageing product range

The company sells clinically validated anti-ageing products for hair, skin and body.
consumer health segment overview
INVESTMENT OVERVIEW: CDY The Big Picture
The company's consumer health segments operates through subsidiary Advangen

Cellmid Ltd (ASX:CDY) has three wholly owned subsidiaries operating in two distinct business segments – (1) consumer health; and (2) pre-clinical therapeutic assets.

The consumer health segment generates revenue by selling anti-ageing functional cosmetics and consumer health products for hair, face and wellbeing.

The segment generated $5.64 million in revenue in FY2018 and as Cellmid expands its product range and selling markets, it is closing in on profitability.

READ: Cellmid board members hoover up company stock

Cellmid’s product range features évolis® and Fillerina®.

évolis® is a clinically validated, TGA listed portfolio of hair care treatment products specifically formulated as an anti-ageing hair solution.

The product range is sold across Australia, New Zealand, Japan, China and the US.

Fillerina® is the first non-injectable transdermal filler that has been clinically validated to reduce wrinkles and increase facial volume.

In April 2018, Cellmid entered into a distribution agreement for Fillerina to be sold in Australia and New Zealand through Labo International, a European cosmetics company.

READ: Cellmid set to launch its anti-aging hair care range in major stores across the U.S.

At the end of August 2018, Cellmid commenced the instore launch of its anti-ageing hair care range, évolis® Professional in Neiman Marcus and Soft Surroundings stores across the US.

As part of the launch, a series of experiential marketing events will be held in flagship Neiman Marcus stores in Hawaii (Ala Moana), California (Fashion Island), Florida (Orlando) and Texas (Northpark and Houston).

Cellmid’s CEO Maria Halasz said: “Store presence is expected to increase sales significantly from what has been a very successful online launch of the évolis® Professional products in Neiman Marcus and Soft Surroundings.”

Monetising its pre-clinical therapeutic assets

Cellmid’s second business segment, pre-clinical therapeutic assets refers to its midkine (MK) portfolio.

The évolis® hair growth product range was developed using FGF5 related intellectual property.

Cellmid aims to follow in the footsteps of FGF5 by commercialising its MK portfolio through various deals and partnerships.

Two separate entities setup to make deal transactions easier

Lyramid Limited and Kinera Limited are Cellmid’s wholly-owned subsidiaries that own and develop MK related research and development programs.

Kinera holds MK protein for the treatment of heart failure, chronic heart conditions and ischemic diseases.

Lyramid holds MK antibodies for the treatment of myocarditis, cancer, fibrosis, chronic kidney disease and associated conditions.

READ: Cellmid’s study confirms effectiveness of lead antibody against rare chronic kidney disease

In September 2018, Cellmid received positive efficacy results from its lead anti-midkine antibody, CAB102, against focal segmental glomerulosclerosis (FSGS), a rare kidney disease.

Notably, the humanised antibody reduced the area of kidney injury 3-fold compared to vehicle-treated control mice with FSGS, while renal function was improved.

This was a critical step in progressing Cellmid’s antibody assets towards clinical trials in kidney patients.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
pills
November 07 2018
'I joke that Wall Street and Big Pharma didn't wake up today wondering where that next $10 million Canadian product is going to come from, but we do,' says CEO Doug Janzen
bacteria
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use